Plasma levels of thromboxane A2 on admission are associated with no-reflow after primary percutaneous coronary intervention

Giampaolo Niccoli, Simona Giubilato, Eleonora Russo, Cristina Spaziani, Andrea Leo, Italo Porto, Antonio M. Leone, Francesco Burzotta, Silvia Riondino, Fabio Pulcinelli, Luigi M. Biasucci, Filippo Crea

Research output: Contribution to journalArticle

Abstract

Aims: Thromboxane A2 (TXA2) is a key mediator of platelet activation and aggregation, and an important mediator of platelet-induced coronary artery constriction. We sought to investigate whether baseline plasma levels of TXA2 are associated with coronary no-reflow after primary percutaneous coronary intervention (PPCI). Methods and results: A total of 47 consecutive patients (age, 62.5 ± 12.7; male sex, 76.6%) admitted to our hospital for a first ST-segment elevation myocardial infarction and undergoing PPCI within 12 h of onset of symptoms were enrolled. Admission TXA2 plasma levels were measured by enzyme-linked immunosorbent assay (ELISA). Angiographic no-reflow was defined as a final TIMI flow of ≤2 or final TIMI flow of 3 with a myocardial blush grade of

Original languageEnglish
Pages (from-to)1843-1850
Number of pages8
JournalEuropean Heart Journal
Volume29
Issue number15
DOIs
Publication statusPublished - Aug 2008

Fingerprint

Thromboxane A2
Percutaneous Coronary Intervention
Platelet Activation
Platelet Aggregation
Constriction
Coronary Vessels
Blood Platelets
Enzyme-Linked Immunosorbent Assay

Keywords

  • Acute myocardial infarction
  • No-reflow
  • Platelets
  • Primary percutaneous coronary intervention
  • Thromboxane A2

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Plasma levels of thromboxane A2 on admission are associated with no-reflow after primary percutaneous coronary intervention. / Niccoli, Giampaolo; Giubilato, Simona; Russo, Eleonora; Spaziani, Cristina; Leo, Andrea; Porto, Italo; Leone, Antonio M.; Burzotta, Francesco; Riondino, Silvia; Pulcinelli, Fabio; Biasucci, Luigi M.; Crea, Filippo.

In: European Heart Journal, Vol. 29, No. 15, 08.2008, p. 1843-1850.

Research output: Contribution to journalArticle

Niccoli, G, Giubilato, S, Russo, E, Spaziani, C, Leo, A, Porto, I, Leone, AM, Burzotta, F, Riondino, S, Pulcinelli, F, Biasucci, LM & Crea, F 2008, 'Plasma levels of thromboxane A2 on admission are associated with no-reflow after primary percutaneous coronary intervention', European Heart Journal, vol. 29, no. 15, pp. 1843-1850. https://doi.org/10.1093/eurheartj/ehn325
Niccoli, Giampaolo ; Giubilato, Simona ; Russo, Eleonora ; Spaziani, Cristina ; Leo, Andrea ; Porto, Italo ; Leone, Antonio M. ; Burzotta, Francesco ; Riondino, Silvia ; Pulcinelli, Fabio ; Biasucci, Luigi M. ; Crea, Filippo. / Plasma levels of thromboxane A2 on admission are associated with no-reflow after primary percutaneous coronary intervention. In: European Heart Journal. 2008 ; Vol. 29, No. 15. pp. 1843-1850.
@article{f5f97d4a0ee24719a9dd79b9bb57bb9a,
title = "Plasma levels of thromboxane A2 on admission are associated with no-reflow after primary percutaneous coronary intervention",
abstract = "Aims: Thromboxane A2 (TXA2) is a key mediator of platelet activation and aggregation, and an important mediator of platelet-induced coronary artery constriction. We sought to investigate whether baseline plasma levels of TXA2 are associated with coronary no-reflow after primary percutaneous coronary intervention (PPCI). Methods and results: A total of 47 consecutive patients (age, 62.5 ± 12.7; male sex, 76.6{\%}) admitted to our hospital for a first ST-segment elevation myocardial infarction and undergoing PPCI within 12 h of onset of symptoms were enrolled. Admission TXA2 plasma levels were measured by enzyme-linked immunosorbent assay (ELISA). Angiographic no-reflow was defined as a final TIMI flow of ≤2 or final TIMI flow of 3 with a myocardial blush grade of",
keywords = "Acute myocardial infarction, No-reflow, Platelets, Primary percutaneous coronary intervention, Thromboxane A2",
author = "Giampaolo Niccoli and Simona Giubilato and Eleonora Russo and Cristina Spaziani and Andrea Leo and Italo Porto and Leone, {Antonio M.} and Francesco Burzotta and Silvia Riondino and Fabio Pulcinelli and Biasucci, {Luigi M.} and Filippo Crea",
year = "2008",
month = "8",
doi = "10.1093/eurheartj/ehn325",
language = "English",
volume = "29",
pages = "1843--1850",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "15",

}

TY - JOUR

T1 - Plasma levels of thromboxane A2 on admission are associated with no-reflow after primary percutaneous coronary intervention

AU - Niccoli, Giampaolo

AU - Giubilato, Simona

AU - Russo, Eleonora

AU - Spaziani, Cristina

AU - Leo, Andrea

AU - Porto, Italo

AU - Leone, Antonio M.

AU - Burzotta, Francesco

AU - Riondino, Silvia

AU - Pulcinelli, Fabio

AU - Biasucci, Luigi M.

AU - Crea, Filippo

PY - 2008/8

Y1 - 2008/8

N2 - Aims: Thromboxane A2 (TXA2) is a key mediator of platelet activation and aggregation, and an important mediator of platelet-induced coronary artery constriction. We sought to investigate whether baseline plasma levels of TXA2 are associated with coronary no-reflow after primary percutaneous coronary intervention (PPCI). Methods and results: A total of 47 consecutive patients (age, 62.5 ± 12.7; male sex, 76.6%) admitted to our hospital for a first ST-segment elevation myocardial infarction and undergoing PPCI within 12 h of onset of symptoms were enrolled. Admission TXA2 plasma levels were measured by enzyme-linked immunosorbent assay (ELISA). Angiographic no-reflow was defined as a final TIMI flow of ≤2 or final TIMI flow of 3 with a myocardial blush grade of

AB - Aims: Thromboxane A2 (TXA2) is a key mediator of platelet activation and aggregation, and an important mediator of platelet-induced coronary artery constriction. We sought to investigate whether baseline plasma levels of TXA2 are associated with coronary no-reflow after primary percutaneous coronary intervention (PPCI). Methods and results: A total of 47 consecutive patients (age, 62.5 ± 12.7; male sex, 76.6%) admitted to our hospital for a first ST-segment elevation myocardial infarction and undergoing PPCI within 12 h of onset of symptoms were enrolled. Admission TXA2 plasma levels were measured by enzyme-linked immunosorbent assay (ELISA). Angiographic no-reflow was defined as a final TIMI flow of ≤2 or final TIMI flow of 3 with a myocardial blush grade of

KW - Acute myocardial infarction

KW - No-reflow

KW - Platelets

KW - Primary percutaneous coronary intervention

KW - Thromboxane A2

UR - http://www.scopus.com/inward/record.url?scp=48749130828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48749130828&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/ehn325

DO - 10.1093/eurheartj/ehn325

M3 - Article

C2 - 18617477

AN - SCOPUS:48749130828

VL - 29

SP - 1843

EP - 1850

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 15

ER -